Dementia and Alzheimer Disease

The assistant professor of neurosurgery at Yale School of Medicine discussed the observations she and colleagues have made of the relationship between microglia and astrocytes in the cell death process.

The 18F-PI-2620 radiotracer’s positive effect on diagnosing and differentiating patients with suspected progressive supranuclear palsy leaves questions about its potential as a PSP progression biomarker.

The investigational Alzheimer disease agent BAN2401 will be assessed in 1400 participants who will be randomized to either the A3 trial or the A45 trial.

The assistant professor of neurosurgery at Yale School of Medicine discussed the current understanding of the process of cell death in the brain, and what players are involved in the removal of dead cells.

The assistant professor of neurosurgery at Yale School of Medicine spoke to the observations she and colleagues made to better understand the process of cell death and corpse removal in the brain.

The University of Miami Miller School of Medicine designated as 1 of the 31 centers of excellence by the National Institute of Aging and will play a huge role in the 1Florida Alzheimer's Disease Research Center.

Neurology News Network for the week ending July 11, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 10, 2020.

Despite the ongoing public health emergency, many of the telehealth policies established by the CARES Act waiver are expiring.

Biogen’s biologics license application for aducanumab is supported by the phase 3 EMERGE and ENGAGE trials. The company has also requested a priority review designation.

New findings indicate that cognitive health in old age depends in part on cognitive development in early life.

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Neurology News Network for the week ending July 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

No differences were observed between the insulin and placebo groups on several clinical outcome measures as well as biomarker evaluations.

People with Down syndrome may be a suitable population for clinical trials for Alzheimer disease as prevalence ranges from 90% to 100% by the seventh decade of life.

In part 2 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center anticipates life with telemedicine after the pandemic and describes the at-home advantage it gives clinicians.

Neurology News Network for the week ending June 27, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.

In part 1 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center discussed how she adapted quickly to optimizing telemedicine for elderly patients with Alzheimer disease and cognitive decline.

Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease.

Compared to participants with ≤1 healthy lifestyle factor, the risk of developing Alzheimer disease was 37% lower in those with 2 or 3, and 60% lower in those with 4 or 5 healthy lifestyle factors.

The Women's Alzheimer's Prevention Center becomes the first medical clinic in the US to offer a women-specific center for Alzheimer disease prevention, research, and caregiving support.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

The drug, previously approved for Parkinson disease psychosis, received breakthrough therapy designation for this new indication.